Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Investigation of INSYS Therapeutics Inc.

By Business Wire | July 5, 2016

Zeldes Haeggquist & Eck, LLP, a shareholder and consumer rights litigation firm, has commenced an investigation into possible violations of the federal securities laws by certain officers and directors at INSYS Therapeutics, Inc.

Insys is a specialty pharmaceutical company that develops and commercializes supportive care products primarily designed to assist patients with pain management. Insys’ core product and source of revenue is Subsys, a form of fentanyl that is sprayed under the tongue.

On June 10, 2016, CNBC and The New York Times reported that two former Insys employees, Jonathan Roper and Fernando Serrano, were arrested on June 9, 2016 on federal anti-kickback charges, accused of paying thousands of dollars to doctors who prescribed the company’s main drug, Subsys through “sham educational programs.” On this news, the company’s share price dropped over 12 percent.

Subsys is approved by the FDA for use only in patients who have cancer and experience pain even though they are on round-the-clock painkillers. However, Insys has been accused of paying doctors to prescribe it for patients who have migraines or even minor neck or back pain.

Federal prosecutors say the case is particularly egregious because it involves the inappropriate marketing of fentanyl, a drug that is 100 times more potent morphine and is incredibly dangerous and highly addictive. Fentanyl is the drug that the musician Prince accidentally overdosed on.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE